Author, as appears in the article.: Vilar-Ribó, L; Cabana-Domínguez, J; Martorell, L; Ramos-Quiroga, JA; Sanchez-Roige, S; Palmer, AA; Vilella, E; Ribasés, M; Muntané, G; Artigas, MS
Department: Medicina i Cirurgia
URV's Author/s: Martorell Bonet, Lourdes / Muntané Medina, Gerard / Vilella Cuadrada, Elisabet
Keywords: Deficit-hyperactivity disorder schizophrenia mortality mendelian randomization genome-wide association disease children childhood adults adhd
Abstract: There is evidence linking ADHD to a reduced life expectancy. The mortality rate in individuals with ADHD is twice that of the general population and it is associated with several factors, such as unhealthy lifestyle behaviors, social adversity, and mental health problems that may in turn increase mortality rates. Since ADHD and lifespan are heritable, we used data from genome-wide association studies (GWAS) of ADHD and parental lifespan, as proxy of individual lifespan, to estimate their genetic correlation, identify genetic loci jointly associated with both phenotypes and assess causality. We confirmed a negative genetic correlation between ADHD and parental lifespan (rg = −0.36, P = 1.41e−16). Nineteen independent loci were jointly associated with both ADHD and parental lifespan, with most of the alleles that increased the risk for ADHD being associated with shorter lifespan. Fifteen loci were novel for ADHD and two were already present in the original GWAS on parental lifespan. Mendelian randomization analyses pointed towards a negative causal effect of ADHD liability on lifespan (P = 1.54e−06; Beta = −0.07), although these results were not confirmed by all sensitivity analyses performed, and further evidence is required. The present study provides the first evidence of a common genetic background between ADHD and lifespan, which may play a role in the reported effect of ADHD on premature mortality risk. These results are consistent with previous epidemiological data describing reduced lifespan in mental disorders and support that ADHD is an important health condition that could negatively affect future life outcomes.
Thematic Areas: Psychiatry and mental health Psychiatry Psicología Pharmacology & pharmacy Pharmacology Neurosciences Medicina ii Medicina i Interdisciplinar General medicine Farmacia Engenharias iv Educação física Ciências biológicas ii Ciências biológicas i
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: gerard.muntane@urv.cat lourdes.martorell@urv.cat elisabet.vilella@urv.cat
Author identifier: 0000-0003-4999-2197 0000-0002-1887-5919
Record's date: 2024-08-03
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://www.nature.com/articles/s41386-023-01555-x
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Neuropsychopharmacology. 48 (7): 981-990
APA: Vilar-Ribó, L; Cabana-Domínguez, J; Martorell, L; Ramos-Quiroga, JA; Sanchez-Roige, S; Palmer, AA; Vilella, E; Ribasés, M; Muntané, G; Artigas, MS (2023). Shared genetic architecture between attention-deficit/hyperactivity disorder and lifespan. Neuropsychopharmacology, 48(7), 981-990. DOI: 10.1038/s41386-023-01555-x
Article's DOI: 10.1038/s41386-023-01555-x
Entity: Universitat Rovira i Virgili
Journal publication year: 2023
Publication Type: Journal Publications